Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 304 participants.

Also called NCT01517373

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 304 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01517373
  • EudraCT 2011-005206-30
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Canada, Hungary, India, Slovakia, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01517373. Randomized; triple masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2013-01 (actual). Results posted on 2017-01-31.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
PF-04937319 10 mg
Intervention (Drug)
PF-04937319 50 mg
Intervention (Drug)
PF-04937319 100 mg
Intervention (Drug)
Glimepiride
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01517373
Content hash
b2211f82680dfef28fe45235fc0a5c8cac5d2ba60389d46c73833ce4426b1b42